e-learning
resources
Virtual 2020
Pre-Congress Content
Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.
T. Simpson (London, United Kingdom), A. West (London, United Kingdom)
Source:
Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Session:
Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Session type:
E-poster session
Number:
442
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Simpson (London, United Kingdom), A. West (London, United Kingdom). The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.. 442
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Gender perspective in Interstitial Lung Diseases (ILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used
Source: International Congress 2017 – Rare diseases
Year: 2017
Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Dedicated Pulmonary Rehabilitation for Patients with Interstitial Lung Disease in a District General Hospital
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Childhood Interstitial Lung disease: A Tertiary Single Center Experience
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Evaluation of three dyspnea questionnaires in the progression of Interstitial Lung Diseases.
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Unclassifiable Interstitial Lung Disease (ILD). Why?
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Autoantibodies in Interstitial Lung Diseases
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021
Inmunosuppresor therapy effectivness in Interstitial Lung Disease (ILD) associated Connective Tisuue Disease(CTD).
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014
A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Multicenter Registry of Interstitial Lung Diseases in Brazil
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Lung Cancer Screening Programs: a missed “window” to diagnose Obstructive Lung Disease. The NLST-ACRIN experience.
Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms
Year: 2018
Integrating Ambulatory Oxygen assessments into a specialist Interstitial Lung Disease (ILD) clinic
Source: Virtual Congress 2020 – Aspects of pulmonary rehabilitation: part 1
Year: 2020
Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome
Source: International Congress 2014 – ILDs 1
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept